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open access article under the CC BY-NSummary Female sex hormones play an important role in the aetiology and pathophysiology
of a variety of musculoskeletal degenerative diseases. Postmenopausal women show acceler-
ated disc degeneration due to relative oestrogen deficiency, resulting in narrower interverte-
bral disc space in women than age-matched men, increased prevalence of spondylolisthesis,
and increased prevalence of facet joint osteoarthritis. Postmenopausal women also show high-
er osteoporosis related spine fracture rate, particularly at the thoracicelumbar junction site. I
propose the concept that low back pain (LBP) is more prevalent in postmenopausal women
than age-matched men and is associated with the physiological changes caused by the rela-
tively lower level of sex hormones after menopause in women. Considering hormone replace-
ment treatment (HRT)’s consistent efficacy reported with menopause-associated
osteoarthritis, an in-depth understanding of the role of the gonadal hormones in LBP modula-
tion warrants further study. HRT initiated at early postmenopausal phase may be protective for
recurring LBP. If this is the case, further costebenefit analysis should be performed for optimal
HRT regimen in cases of women with high risk of recurring severe LBP.
ª 2016 The Author(s). Published by Elsevier (Singapore) Pte Ltd on behalf of Chinese Speaking
Orthopaedic Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Oestrogens participate in a variety of biological processes
through different molecular mechanisms. Oestrogen has
favourable effects on the lipid profile, antioxidant activity,of Imaging and Interventional Ra
ries, Hong Kong Special Administr
k.edu.hk.
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2 Y.X.J. Wangprevalence of osteoarthritis (OA) is higher among women
than among men, and this prevalence increases consider-
ably after menopause [2,3]. Moreover, with the same de-
gree of radiographic damage, OA is also more symptomatic
in women [2,3]. Young men are more susceptible to disc
degeneration than young women, probably due to
increased mechanical stress and physical injury [4e6].
However, recent evidence suggests that disc degeneration
is common or more severe in elderly women than in elderly
men [7,8]. Postmenopausal women show accelerated disc
degeneration due to relative oestrogen deficiency [9,10].
Postmenopausal women also show narrower intervertebral
disc space than age-matched men [8,11], increased prev-
alence of spondylolisthesis [12e14], and increased preva-
lence of facet joint arthritis [15].
In the literature, the reported population-based low
back pain (LBP) prevalence varies as it depends on the
definitions of LBP as well as the survey method. A number
of reports suggest that women have higher prevalence of
LBP than men [16e19], despite the fact that young and
middle-aged men have higher prevalence and more severe
intervertebral disc degeneration [4e6]. The higher LBP
prevalence in women is probably due to many factors,
including heightened pain sensitivity among women
[20,21], menstrual cycle fluctuations, biologic response and
stress to pregnancy and childbearing, and perimenopausal
abdominal weight gain [19]. Recently, it has been show that
genetics also plays a role in the development of LBP
[1,22,23]. A very recent systematic review, which was
limited to population based studies with the same LBP
criteria applied to both men and women in the same
community, demonstrates, compared with middle-aged
individuals, a further increased LBP prevalence in women
than in men was noted after menopause age [24]. By
contrast, in an evaluation of pain characteristics of adults
aged  65 years referred to a tertiary pain care clinic, the
older patients had relatively more physical problems
concordant with their complaints, but fewer psychological
factors contributing to disability than the younger patients
[25,26].
In some studies, LBP is strikingly more prevalent in
postmenopausal women than age-matched men. In 1969,
Lawrence [27] surveyed 713 men and 809 women aged  35
years with lumbar radiography in Manchester, UK. Back-
ehipesciatic pain was present at the time of the survey in
79 (11%) of the men and in 153 (19%) of the women. In those
with pain at the time of the survey, the incidence had risen
up to age 40 years in men and then remained constant, but
in women it continued to rise sharply up to and over the age
of 65 years (Figure S1A). In 1995, Papageorgiou et al [28]
reported the South Manchester Back Pain Survey with a
study population of 4501 (age 18e75 years). The 1-month
period prevalence of LBP was 31.2%, 33.1%, 38.5%, and
34.9% for the age ranges of 18e29 years, 30e44 years,
45e59 years, and  60 years, respectively, for men; 32.2%,
41.5%, 49.2%, and 43.7% for the age ranges of 18e29 years,
30e44 years, 45e59 years, and  60 years, respectively, for
women. In 2010, Cho et al [29] published LBP data collected
for 4181 individuals from a rural farming community in
Korea. The participants had a mean age of 56.6 years and
55.5% were women. Six-month prevalence of LBP was 38.5
% for men and 55.6 for women. The prevalence of LBPincreased significantly with age in women (Figure S1B).
Data from the Osteoporotic Fractures in Men (Hong Kong)
and Osteoporotic Fractures in Women (Hong Kong) Studies
were published in 2013 [8]; 2000 Chinese men and 2000
Chinese women, aged  65 years, were prospectively
recruited from local communities for a prospective cohort
study from August 2001 to March 2003. The LBP prevalence
was 30.6% for men and 53.3% for women (p < 0.001). While
postmenopausal women also show higher osteoporosis-
related spine fracture rate compared with age-matched
men, and vertebral fracture is a known cause of back
pain and related disability [30], the accelerated spine
degeneration caused by the relatively lower level of sex
hormones after menopause in women [9,10], including
narrower intervertebral disc space, higher lumbar spondy-
lolisthesis prevalence, and increased prevalence of facet
joint osteoarthritis, may be an additional source of LBP in
elderly women.
Oestrogen with or without a progestogen prevents early
postmenopausal bone loss and augments bone mass in late
postmenopause as effectively as the bisphosphonates [29].
Hormone replacement treatment (HRT) has consistently
been shown to be protective against menopause-associated
OA [31e35].
However, to date the clinical data on HRT’s effects on
LBP remain contradictory. For example, Baron et al [36]
found that women on HRT maintained intervertebral disc
height compared with untreated postmenopausal women.
They suggested that the oestrogenic milieu may be relevant
because of the significant impact it has on the hydrophilic
glycosaminoglycans, the water content, collagen, and
elastin of the intervertebral discs. The maintenance of
adequate disc height may allow the intervertebral discs to
retain their discoid shape and viscoelastic function, con-
taining vertical forces which may threaten spinal archi-
tecture leading to vertebral body compression fractures
[36]. Kyllo¨nen et al’s [37] longitudinal clinical study sup-
ports that oestrogeneprogestin replacement therapy was
beneficial for lumbar spine mobility. In an experimental
study, Li et al [38] reported that resveratrol, a phytoes-
trogen, is a potent anabolic mediator of bovine interver-
tebral disc cartilage homeostasis to slow the progression of
disc degeneration. However, in one study Musgrave et al
[39] reported that women taking HRT had more back pain
and back pain-related disability than did those not taking
HRT. In another study Symmons et al [40] also reported that
oestrogen use was more common in the group reporting
back pain than in the group without back pain. Considering
that HRT is known to decrease vertebral fracture rate [31],
and protect intervertebral disc [36], and maybe also facet
joint [12], Musgrave et al’s [39] and Symmons et al’s [40]
findings look counterintuitive. In one systemic review,
Bressler et al [25] noted that there is an under-
representation of the older population in the LBP pain
literature. They stressed the need for future studies to
improve the reporting of age information to make preva-
lence studies more informative and applicable.
The expert views of HRT have evolved during the past 10
years since the publication of Women’s Health Initiative
trials [41,42]. Since the initial publication of the Women’s
Health Initiative hormone trial results, multiple secondary
analyses have yielded interesting data that suggested that
Low back pain in postmenopausal women 3the risk of coronary heart disease was dependent upon both
the timing of initiating hormone exposure as well as the age
of the woman at the time of HRT initiation [43,44]. Spe-
cifically, in the oestrogen-alone trial, a nonstatistically
significant reduction in coronary heart disease risk was
noted in participants aged 50e59 years [44]. Dose regimen,
combination of oestrogen with progestins versus oestrogen
alone, the administration route, and duration of treatment
such as the choice of repetitive or periodic administration
simulating the menstrual cycle are some of the factors that
may be involved in benefit discrepancies. The Estrogen and
Thromboembolism Risk study confirmed that oral oes-
trogens increased venous thromboembolism risk, whereas
transdermal oestrogens had little or no impact on the
development of thrombosis [45]. Recent Korean data do not
support HRT history for the risk of breast cancer in women
[46]. The presence of gene polymorphisms may also be
implicated. HRT may benefit a large number of post-
menopausal women, but a subset of women may have
higher risk of cardiovascular and thrombotic complications
[47]. Oestrogen receptor modulators and phytoestrogens
may retain the desired effects but avoid undesirable ef-
fects [48]. Considering HRT’s efficacy reported with
menopause-associated OA in many studies, an in-depth
understanding of the role of the gonadal hormones in LBP
modulation warrants further study. HRT initiated at early
postmenopausal phase may be protective for recurring LBP,
as LBP tends to be a recurring phenomenon in nature. HRT
protects both bone [31] and disc tissue [12,36]. If this is the
case, further costebenefit analysis should be performed for
optimal HRT regimen in cases of women with high risk of
recurring severe LBP.Conflicts of interest
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